Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24401086 | 0.82 | GPR119 (0.51) | LOXLOXL2LIPENAMPTMCHR1 | |
| SCHEMBL12367571 | 0.81 | NAMPT (0.46) | LIPESIGMAR1NAMPTMCHR1 | |
| SCHEMBL17214693 | 0.80 | LOX (0.55) | OPRK1LOXLOXL2KCNH2MCHR1 | |
| SCHEMBL12367663 | 0.79 | OPRK1 (0.42) | OPRK1LIPEKCNH2NAMPT | |
| SCHEMBL2585954 | 0.79 | LOX (0.61) | OPRK1LOXLOXL2KCNH2 | |
| SCHEMBL5534680 | 0.79 | OPRK1 (0.59) | OPRK1HRH1CCR3SIGMAR1KCNH2 | |
| SCHEMBL12367605 | 0.78 | OPRK1 (0.39) | OPRK1LIPESIGMAR1NAMPT | |
| SCHEMBL12390482 | 0.78 | SIGMAR1 (0.56) | HRH1CCR3SIGMAR1KCNH2 | |
| SCHEMBL12367570 | 0.77 | ACHE (0.44) | OPRK1HRH1NAMPT | |
| SCHEMBL29483271 | 0.76 | LOX (0.44) | LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | OPRK1 252/4885LOX 735/4885LOXL2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.